A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder

NCT03093025 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

51

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Major Depressive Disorder

Interventions

DRUG: TS-121 10 mg
DRUG: TS-121 50 mg
DRUG: Placebo

Sponsor

Taisho Pharmaceutical R&D Inc.